Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 3 , Pages 180-183, May 2006

Treatment of stage I seminoma: A 15-year review

Presented at the 2004 Annual Scientific Meeting of the Canadian Association of Radiation Oncologists.

  • Ibraheem Alomary, M.D.

      Affiliations

    • Radiation Oncology Department, Ottawa Hospital Regional Cancer Center, Ottawa, Canada
    • Faculty of Medicine, University of Ottawa, Ottawa, Canada
    • Corresponding Author InformationCorresponding author. Tel.: +1-613-737-7700 ext. 6954; fax: +1-613-247-3511.
  • ,
  • Rajiv Samant, M.D.

      Affiliations

    • Radiation Oncology Department, Ottawa Hospital Regional Cancer Center, Ottawa, Canada
    • Faculty of Medicine, University of Ottawa, Ottawa, Canada
  • ,
  • Victor Gallant

      Affiliations

    • Radiation Oncology Department, Ottawa Hospital Regional Cancer Center, Ottawa, Canada

Received 21 February 2005; received in revised form 29 April 2005; accepted 3 May 2005.

Abstract 

Purpose

To review the treatment and outcomes in patients with stage I seminoma after orchidectomy.

Methods

A retrospective chart review of all patients with stage I seminoma referred for initial treatment during the last 15 years was performed. Initial treatment approaches and outcomes were analyzed. Comparisons were made between patients treated with adjuvant radiotherapy and those receiving no adjuvant therapy (surveillance group).

Results

A total of 150 patients with stage I seminoma was seen between 1989 and 2003. Median age at diagnosis was 37.5 years (range 19–79), with a median follow-up of 54 months (range 1–162). Of the patients, 71% were treated with adjuvant radiotherapy, and 29% were placed on a surveillance protocol. The 5-year relapse-free survival and overall survival for the entire group were 95% and 100%, respectively. The 5-year relapse-free survival for the adjuvant radiotherapy group was 100% compared with 79% for the surveillance group (P < 0.001). Of the 6 patients who had a relapse, 5 were salvaged with radiation, but 1 required chemotherapy as well. One patient who had a relapse is currently refusing treatment for recurrence.

Conclusions

Our results confirm the excellent prognosis for patients with stage I seminoma and indicate that surveillance does not compromise survival. This result adds to the evidence that surveillance is a good option for many patients and also supports our current approach, which favors surveillance for most patients with stage I seminoma after orchidectomy who are willing to go on our surveillance protocol.

Keywords:  Radiotherapy , Surveillance , Stage I seminoma

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was supported by the Radiation Oncology Research Fund of The Ottawa Hospital regional Cancer Centre and the Ottawa Radiation Oncology Partners.

PII: S1078-1439(05)00103-1

doi:10.1016/j.urolonc.2005.05.010

Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 3 , Pages 180-183, May 2006